Potent and selective glycogen synthase kinase-3 (GSK-3) inhibitor (Ki
= 31 nM for GSK-3α
); competes with ATP. Has minimal activity against 24 other protein kinases (IC50
> 10 μ
M). Stimulates glycogen synthesis, gene transcription and is neuroprotective.
The technical data provided above is for guidance only. For batch specific data refer to the Certificate of Analysis.
All Tocris products are intended for laboratory research use only.
Sold for research purposes under agreement from GlaxoSmithKline
Regulation and function of glycogen synthase kinase-3 isoforms in neuronal survival.
Liang and Chuang
Selective small molecule inhibitors of glycogen synthase kinase-3 modulate glycogen metabolism and gene transcription.
Coghlan et al.
Selective small-molecule inhibitors of glycogen synthase kinase-3 activity protect primary neurones from death.
Cross et al.
The citations listed below are publications that use Tocris products. Selected citations for SB 415286 include:
Showing Results 1 - 10 of 20